Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 18, 2009, Pages 7619-7623

  Koistoe, Simon E ^a   Ridha, Basil H ^a   Bellotti, Vittorio ^a,d   Wang, Nan ^b,e   Robinson, Carol V ^b   Crutch, Sebastian J ^a   Keir, Geoffrey ^c   Kukkastenvehmas, Rutta ^a   Gallimore, J Ruth ^a   Hutchinson, Winston L ^a   Hawkins, Philip N ^a   Wood, Stephen P ^a   Rossor, Martin N ^a   Pepys, Mark B ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF PAVIA   (Italy)

^e Argenta Discovery Ltd   (United Kingdom)

Author keywords

Bis(D proline); Clinical study; Neurodegenerative disease

Indexed keywords

1 [6 (2 CARBOXYPYRROLIDIN 1 YL) 6 OXO HEXANOYL]PYRROLIDINE 2 CARBOXYLIC ACID; PHOSPHOTHREONINE; PROLINE DERIVATIVE; SERUM AMYLOID P; TAU PROTEIN; UNCLASSIFIED DRUG; CARBOXYLIC ACID; PYRROLIDINE DERIVATIVE; R 1 (6 (R 2 CARBOXYPYRROLIDIN 1 YL) 6 OXOHEXANOYL)PYRROLIDINE 2 CARBOXYLIC ACID; R-1-(6-(R-2-CARBOXYPYRROLIDIN-1-YL)-6-OXOHEXANOYL)PYRROLIDINE-2-CARBOXYLIC ACID;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CROSS LINKING; DEGENERATIVE DISEASE; FEMALE; HUMAN; IN VIVO STUDY; INJECTION SITE DISCOMFORT; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; BLOOD; CHEMISTRY; CIRCULAR DICHROISM; DRUG ANTAGONISM; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PILOT STUDY; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ALZHEIMER DISEASE; CARBOXYLIC ACIDS; CIRCULAR DICHROISM; CRYSTALLOGRAPHY, X-RAY; HUMANS; MASS SPECTROMETRY; MIDDLE AGED; PILOT PROJECTS; PROTEIN CONFORMATION; PYRROLIDINES; SERUM AMYLOID P-COMPONENT;

EID: 66149084427     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0902640106     Document Type: Article

References (41)

1. Pepys MB, et al. (1997) Amyloid P component. A critical review. Amyloid: IntJ Exp Clin Invest 4:274-295.
2. Hawkins PN, et al. (1994) Concentration of serum amyloid P component in the CSF as a possible markerof cerebral amyloid depositsin Alzheimer'sdisease. Bio chem Biophys Res Commun 201:722-726.
3. Coria F, et al. (1988) Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 58:454-458.
4. Duong T, Pommier EC, Scheibel AB (1989) Immunodetection of the amyloid P component in Alzheimer's disease. Acta Neuropathol 78:429-437.
5. Kalaria RN, Grahovac I (1990) Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood-brain barrier in Alzheimer's disease. Brain Res 516:349-353.
6. Kalaria RN, Galloway PG, Perry G (1991) Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders. Neuropathol Appl Neurobiol17:189-201.
7. Duong T, Doucette T, Zidenberg NA, Jacobs RW, Scheibel AB (1993) Microtubule- associated proteins tau and amyloid P component in Alzheimer's disease. Brain Res 603:74-86.
8. Perlmutter LS, Barron E, Myers M, Saperia D, Chui HC (1995) Localization of amyloid P component in human brain: vascular staining patterns and association with Alzheimer's disease lesions. J Comp Neurol 352:92-105.
9. Hamazaki H (1995) Ca2+-dependent binding of human serum amyloid P component to Alzheimer's /3-amyloid peptide. J Biol Chem 270:10392-10394.
10. 2+-binding region of human serum amyloid P component and other pentraxins. Protein Sci 1:700-709.
11. Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents prote- olysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. Proc Natl Acad Sci USA 92:4299-4303.
12. Hamazaki H (1995) Amyloid P component promotes aggregation of Alzheimer's /3-amyloid peptide. Biochem Biophys Res Commun 211:349-353.
13. Botto M, et al. (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 3:855-859.
14. Urbanyi Z, Lakics V, Erdo SL (1994) Serum amyloid P component-induced cell death in primary cultures of rat cerebral cortex. Eur J Pharmacol 270:375-387.
15. Duong T, Acton PJ, Johnson RA (1998) The in vitro neuronal toxicity of pentraxins associated with Alzheimer's disease brain lesions. Brain Res 813:303-312.
16. Urbanyi Z, et al. (2003) Serum amyloid P component induces neuronal apoptosis and beta-amyloid immunoreactivity. Brain Res 988:69-77.
17. Urbanyi Z, et al. (2007) Serum amyloid P component induces TUNEL-positive nuclei in rat brain after intrahippocampal administration. Brain Res 1145:221-226.
18. Pisalyaput K, Tenner AJ (2008) Complement component C1q inhibits f-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem 104:696-707.
19. 1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol 105:135-144.
20. StGeorge-Hyslop PH, Morris JC (2008) Will anti-amyloid therapies work for Alzheimer's disease? Lancet 372:180-182.
21. Pepys MB, et al. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254-259.
22. Kimura M, et al. (1999) Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. Neurosci Lett 273:137-139.
23. Kalaria RN, Golde TE, Cohen M, Younkin LH, Younkin S (1991) Absence of detectable mRNA of serum amyloid P component (SAP) in human brain, choroid plexus, and meninges suggests that the presence of SAP in CSF is due to transport across the blood-brain barrier. J Neuropathol Exp Neurol 50:339.
24. Yasojima K, Schwab C, McGeer EG, McGeer PL (2000) Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 887:80-89.
25. Pepys MB (2005) In Amyloid and Amyloidosis, edsGrateau G, Kyle RA, Skinner M (CRC Press, Boca Raton, FL), pp 488-490.
26. Hutchinson WL, Noble GE, Hawkins PN, Pepys MB (1994) The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest 94:1390-1396.
27. Pepys MB, et al. (1994) Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 91:5602-5606.
28. Berriman J, et al. (2003) Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-β structure. Proc Natl Acad Sci USA 100:9034-9038.
29. GoedertM,Spillantini MG, CairnsNJ,CrowtherRA(1992)Tau proteinsofAlzheimerpaired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8:159-168.
30. Goedert M, Klug A, Crowther RA (2006) Tau protein, the paired helical filament and Alzheimer's disease. J Alzheimers Dis 9:195-207.
31. Green AJ, Keir G, Thompson EJ (1997) A specific and sensitive ELISA for measuring S-100b in cerebrospinal fluid. J Immunol Methods 205:35-41.
32. Petzold A, Keir G, Lim D, Smith M, Thompson EJ (2003) Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern. Brain Res Bull 61:281-285.
33. Folstein MF, Folstein SE, McHugh PR (1975) ''Mini-mental state.'' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189 -198.
34. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry141:1356 -1364.
35. de Beer FC, Pepys MB (1982) Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods 50:17-31.
36. Hawkins PN, Tennent GA, Woo P, Pepys MB (1991) Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin Exp Immunol 84:308-316.
37. Hutchinson WL, Hohenester E, Pepys MB (2000) Human serum amyloid P componentis a single uncomplexed pentamer in whole serum. Mol Med 6:482-493.
38. Ashton AW, Boehm MK, Gallimore JR, Pepys MB, Perkins SJ (1997) Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J Mol Biol 272:408-422.
39. Hernandez H, Robinson CV (2007) Determining the stoichiometry and interactions of macromolecular assemblies from mass spectrometry. Nat Protoc 2:715-726.
40. Hawkins PN, Myers MJ, Epenetos AA, Caspi D, Pepys MB (1988) Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med 167:903-913.
41. Reay P (1982) Use of N-bromosuccinimide for the iodination of proteins for radioim- munoassay. Ann Clin Biochem 19:129 -133.